Screening frequency could range from one-time only screening among people at low risk for tuberculosis exposure to annual screening among those at continued risk.
To mark the observance, there were useful status reports and news of a high-level group that will lead a stronger push against TB in high-burden countries.
The rise follows a decline earlier in the pandemic, which may have contributed to delayed or missed diagnoses.
A collaboration between NGOs and a diagnostic test maker will provide rapid molecular TB tests to high-burden countries at a reduced price.
In a randomized trial conducted in five countries, a 2-month drug regimen was found to be non-inferior to the standard 6-month treatment.
Also, Shionogi announces that the novel antibiotic cefiderocol is now available in Denmark for treating infections caused by gram-negative bacteria in patients with limited treatment options.
There are currently 16 vaccine candidates in clinical development, but progress has been constrained by lack of funding and attention.
The regimen was recently recommended by the WHO for treating patients with drug-resistant TB.
The pact will help lower the cost of two shorter treatment regimens for drug-resistant tuberculosis, broadening access.
Despite the milestone, funding remains far short of what's needed, according to a new report.
